Astria Therapeutics, Inc.ATXSNASDAQ
LOADING
|||
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
4.26%
↑ 109% above average
Average (39q)
-48.39%
Historical baseline
Range
High:95.61%
Low:-1794.45%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 4.26% |
| Q2 2025 | 1.95% |
| Q1 2025 | -31.54% |
| Q4 2024 | -4.45% |
| Q3 2024 | -1.50% |
| Q2 2024 | -21.30% |
| Q1 2024 | 36.56% |
| Q4 2023 | -77.19% |
| Q3 2023 | -41.07% |
| Q2 2023 | -12.32% |
| Q1 2023 | 15.65% |
| Q4 2022 | -10.55% |
| Q3 2022 | -6.64% |
| Q2 2022 | 26.58% |
| Q1 2022 | -61.45% |
| Q4 2021 | -20.58% |
| Q3 2021 | -5.42% |
| Q2 2021 | 95.61% |
| Q1 2021 | -1794.45% |
| Q4 2020 | 17.34% |
| Q3 2020 | -14.24% |
| Q2 2020 | -19.57% |
| Q1 2020 | -20.30% |
| Q4 2019 | -1.47% |
| Q3 2019 | 8.65% |
| Q2 2019 | -18.10% |
| Q1 2019 | 0.36% |
| Q4 2018 | -6.71% |
| Q3 2018 | 12.35% |
| Q2 2018 | 15.33% |
| Q1 2018 | -39.20% |
| Q4 2017 | 21.66% |
| Q3 2017 | -0.62% |
| Q2 2017 | 11.45% |
| Q1 2017 | 10.28% |
| Q4 2016 | -4.26% |
| Q3 2016 | 10.86% |
| Q2 2016 | -0.29% |
| Q1 2016 | 1.96% |
| Q4 2015 | -13.21% |